Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes

By  

PEDIATRIC DIABETES (ELECTRONIC), Vol. 16, Iss. 3, 2015-05 ,pp. : 164-176

John Wiley & Sons Inc

Access to resources Recommend Favorite

Insulin degludec/insulin aspart produces a dose‐proportional glucose‐lowering effect in subjects with type 1 diabetes mellitus

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 659-664

John Wiley & Sons Inc

Access to resources Recommend Favorite

A European, multicentre, retrospective, non‐interventional study (EU‐TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 689-697

John Wiley & Sons Inc

Access to resources Recommend Favorite

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD‐ON)

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 16, Iss. 7, 2014-07 ,pp. : 636-644

John Wiley & Sons Inc

Access to resources Recommend Favorite

Insulin degludec improves long‐term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal‐bolus insulin therapy

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 2, 2015-02 ,pp. : 202-206

John Wiley & Sons Inc

Access to resources Recommend Favorite